{"id":5867,"date":"2026-07-25T06:26:35","date_gmt":"2026-07-25T06:26:35","guid":{"rendered":"https:\/\/www.diabetesasia.org\/journal\/?p=5867"},"modified":"2026-07-26T15:45:35","modified_gmt":"2026-07-26T15:45:35","slug":"metformin-as-first-line-therapy-in-gestational-diabetes-mellitus-gdm","status":"publish","type":"post","link":"https:\/\/www.diabetesasia.org\/journal\/metformin-as-first-line-therapy-in-gestational-diabetes-mellitus-gdm\/","title":{"rendered":"Metformin as First-Line Therapy in Gestational Diabetes Mellitus (GDM)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Metformin as First-Line Therapy in Gestational Diabetes Mellitus (GDM)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Comparison Across DIPSI, NICE, SIGN, FIGO, Endocrine Society, SMFM, and ADA Guidelines<br>Rachna Jain*<br>*Consultant Obstetrician &amp; Gynecologist, MBBS, DGO, Jain Hospital &amp; Research Center, Kanpur, India. Email:<br>rachnajai9838@jainhospitals.com<br>Submitted: 28 June 2026; Accepted: 18 July 2026; Published: 24 July 2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DIPSI (Diagnosis &amp; Management of Gestational Diabetes Mellitus, 2021 \u2014 Diabetes in Pregnancy Study Group India, published via FOGSI) does not list metformin as first-line. Insulin is the drug of choice and is recommended for use in pregnancy as it does<br>not cross the placenta (FOGSI\/DIPSI, 2021). [1] Metformin has a secondary role: it is useful for obese women or for women who are already on it, but it should not be prescribed for women with GDM if there is significant organ dysfunction, hypertensive<br>disorders of pregnancy, fetal growth restriction, or other high-risk factors (FOGSI\/DIPSI, 2021). [1]<\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/www.diabetesasia.org\/journal\/wp-content\/uploads\/2026\/07\/Metformin.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Metformin.\"><\/object><a id=\"wp-block-file--media-8c1ba2c8-bdd7-407e-b47b-88b0962a406b\" href=\"https:\/\/www.diabetesasia.org\/journal\/wp-content\/uploads\/2026\/07\/Metformin.pdf\">Metformin<\/a><a href=\"https:\/\/www.diabetesasia.org\/journal\/wp-content\/uploads\/2026\/07\/Metformin.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8c1ba2c8-bdd7-407e-b47b-88b0962a406b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Metformin as First-Line Therapy in Gestational Diabetes Mellitus (GDM) A Comparison Across DIPSI, NICE, SIGN, FIGO, Endocrine Society, SMFM, and ADA GuidelinesRachna Jain**Consultant Obstetrician &amp; Gynecologist, MBBS, DGO, Jain Hospital &amp; Research Center, Kanpur, India. Email:rachnajai9838@jainhospitals.comSubmitted: 28 June 2026; Accepted: 18 July 2026; Published: 24 July 2026 DIPSI (Diagnosis &amp; Management of Gestational Diabetes Mellitus, 2021 \u2014 Diabetes in Pregnancy Study Group India, published via FOGSI) does not list metformin as first-line. Insulin is the drug of choice and is recommended for use in pregnancy as it doesnot cross the placenta (FOGSI\/DIPSI, 2021). [1] Metformin has a secondary role: it is useful for obese women or for women who are already on it, but it should not be prescribed for women with GDM if there is significant organ dysfunction, hypertensivedisorders of pregnancy, fetal growth restriction, or other high-risk factors (FOGSI\/DIPSI, 2021). [1]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,141],"tags":[10,149,42,109,148],"class_list":["post-5867","post","type-post","status-publish","format-standard","hentry","category-blog","category-volume-03-issue-02","tag-dipsi","tag-figo","tag-gdm","tag-metformin","tag-nice"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/posts\/5867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/comments?post=5867"}],"version-history":[{"count":4,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/posts\/5867\/revisions"}],"predecessor-version":[{"id":5889,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/posts\/5867\/revisions\/5889"}],"wp:attachment":[{"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/media?parent=5867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/categories?post=5867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.diabetesasia.org\/journal\/wp-json\/wp\/v2\/tags?post=5867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}